FDA moves toward easing restrictions on certain peptides BioPharma Dive FDA Compliance for Peptide Therapy and BPC 157 Holt Law BPC 157 and ipamorelin under FDA scrutiny Alex Keoskey posted on the topic LinkedIn Don't Ignore an FDA Warning Letter: The Legal Risks Your Business Can't Afford C.F.R. 820.70(i) How To Avoid FDA Warning Letters FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP 1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading